| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
IK-175 (IK175) is an orally bioavailable aryl hydrocarbon receptor (AHR) antagonist with cancer immunomodulatory effects. Aryl hydrocarbon receptor (AHR) is a transcription factor that regulates the activity of multiple innate and adaptive immune cells subsequent to binding to numerous endogenous and exogenous ligands. IK-175exhibited favorable ADME and pharmacokinetic profiles in preclinical species. IK-175 inhibits AHR activity in experimental systems derived from multiple species including mouse, rat, monkey, and humans. In human primary immune cells, IK-175 decreased AHR target gene expression and anti-inflammatory cytokine release and increased proinflammatory cytokine release.
| ln Vitro |
In rat and human cell lines, AHR antagonist 5 free base (Compound A) potently inhibits AHR activity (IC50 of ~35-150 nM). AHR antagonist 5 free base causes an activated T cell state in human T cell tests. Interleukin (IL)-22 and CYP1A1 gene expression are inhibited by AHR antagonist 5 free base, which also causes an increase in pro-inflammatory cytokines such IL-2 and IL-9[1].
|
|---|---|
| ln Vivo |
Several pharmacological, single-dose, and repeated-dose toxicological investigations have assessed AHR antagonist 5 free base (Compound A) in rodent and non-rodent species. These studies include 28-day Good Laboratory Practice (GLP) tests in rats and monkeys. With the exception of the testicular alterations in rats, all changes resolve or begin to resolve after two weeks of stopping the medication[1].
|
| References |
| Molecular Formula |
C25H24FN7
|
|---|---|
| Molecular Weight |
441.50
|
| Exact Mass |
441.207
|
| CAS # |
2247950-42-9
|
| Related CAS # |
AHR antagonist 5;2247953-39-3;AHR antagonist 5 hemimaleate
|
| PubChem CID |
140944699
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
679
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N1C2=C(C=CC=C2)C2=C1CC[C@@H](NC1N3N=CC(C(C)C)=C3N=C(C3=CC(F)=CN=C3)N=1)C2
|
| InChi Key |
QPFPBVPZIIDXGT-QGZVFWFLSA-N
|
| InChi Code |
InChI=1S/C25H24FN7/c1-14(2)20-13-28-33-24(20)31-23(15-9-16(26)12-27-11-15)32-25(33)29-17-7-8-22-19(10-17)18-5-3-4-6-21(18)30-22/h3-6,9,11-14,17,30H,7-8,10H2,1-2H3,(H,29,31,32)/t17-/m1/s1
|
| Chemical Name |
(3R)-N-[2-(5-fluoropyridin-3-yl)-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,3,4,9-tetrahydro-1H-carbazol-3-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~226.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2650 mL | 11.3250 mL | 22.6501 mL | |
| 5 mM | 0.4530 mL | 2.2650 mL | 4.5300 mL | |
| 10 mM | 0.2265 mL | 1.1325 mL | 2.2650 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
